Angiox
bivalirudin
Table of contents
Overview
The marketing authorisation for Angiox has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Angiox
|
| Agency product number |
EMEA/H/C/000562
|
| Active substance |
Bivalirudin
|
| International non-proprietary name (INN) or common name |
bivalirudin
|
| Therapeutic area (MeSH) |
Acute Coronary Syndrome
|
| Anatomical therapeutic chemical (ATC) code |
B01AE06
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
The Medicines Company UK Ltd
|
| Revision |
22
|
| Date of issue of marketing authorisation valid throughout the European Union |
19/09/2004
|
| Contact address | |
Product information
24/10/2016 Angiox - EMEA/H/C/000562 - EMEA/H/C/000562/IB/0070
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary PCI.
Angiox is also indicated for the treatment of adult patients with unstable angina / non-ST-segment-elevation myocardial infarction (UA / NSTEMI) planned for urgent or early intervention.
Angiox should be administered with aspirin and clopidogrel.